Randomized Phase II 2 by 2 Factorial Trial of Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients With Intermediate or High Risk Localized Prostate Cancer (ARP)
Sponsor study identifier
interventional
104
1 country
1
Study Start
January 16, 2026
Actual (reported)Primary Completion
June 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The study is being done to compare the side effects between two different radiation techniques, standard non-adaptive radiation therapy vs. daily adaptive radiation therapy and also comparing two different bladder filling instructions to find out if customized bladder instructions may lead to better treatment outcomes.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 4, 2024
Actual (reported)November 7, 2024
Actual (reported)January 16, 2026
Actual (reported)June 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
January 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Assess the feasibility of randomization to adaptive vs standard radiotherapy localized high-risk prostate cancer.
Accrual and randomization rate will be captured in REDCap database until the goal of 104 participants are randomized. With the accrual rate, we may imply it is feasible to do a larger more definitive and timely randomized control trial.
Accrual period, estimated 3.5 years
Measure and compare the patient reported Acute GU and GI bladder toxicity associated standard (SRT) and Adaptive (ART) radiotherapy for localized prostate cancer.
5 years after participant completes RT
Measure and compare the patient reported Late GU and GI bladder side effects associated standard (SRT) and Adaptive (ART) radiotherapy for localized prostate cancer.
5 years after participant completes RT
Measure and compare the physician reported CTCAE Acute (6 weeks post RT) GU and GI bladder CTCAE toxicity associated standard (SRT) and Adaptive (ART) radiotherapy for localized prostate cancer
5 years after participant completes RT
Determine which bladder filling instructions (BFI) are associated with daily shortest treatment time
approx 4 weeks during treatment of 20 fractions
Determine which BFIs are associated with least rescan and repeat CBCT requirements
approx 4 weeks during treatment of 20 fractions
Adaptive RT \& Standard Bladder Filling Instructions
Adaptive RT and Custom Bladder Filling Instructions
Non Adaptive RT and Standard Bladder Filling Instructions
60 Gy prostate and 44 Gy pelvic nodes with 20 fractions
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
BC Cancer Vancouver
Vancouver, British Columbia, V5Z4E6, Canada
First Submitted
November 4, 2024
First Posted
November 7, 2024
Study Start
January 16, 2026
Actual (reported)Primary Completion
June 2033
Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)
Non Adaptive RT and Custom Bladder Filling Instructions
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 18, 2026
Record last verified: 2026-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: